A5034058277- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Cancer Cells and Metastasis
- Ovarian cancer diagnosis and treatment
- Cancer survivorship and care
- BRCA gene mutations in cancer
- Brain Metastases and Treatment
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Lung Cancer Research Studies
- Cancer-related cognitive impairment studies
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Genetic factors in colorectal cancer
- Multiple and Secondary Primary Cancers
- Global Cancer Incidence and Screening
- COVID-19 and healthcare impacts
- Prostate Cancer Treatment and Research
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Breast Lesions and Carcinomas
Institut Curie
2016-2025
Université Paris Cité
2023-2025
Université Paris Sciences et Lettres
2016-2024
École Normale Supérieure
2023
École Normale Supérieure - PSL
2023
Institut Gustave Roussy
1995-2022
Centre Léon Bérard
2011-2019
Centre Georges François Leclerc
2011-2019
Centre Jean Perrin
2002-2019
Institut Jules Bordet
2019
<h3>Background</h3> The use of warfarin sodium for treating venous thromboembolism in patients with cancer is associated a significant risk recurrence and bleeding. low-molecular-weight heparin secondary prevention may reduce the complication rate. <h3>Objective</h3> To determine whether fixed dose subcutaneous superior to oral prophylaxis thromboembolism. <h3>Methods</h3> In randomized, open-label multicenter trial performed between April 1995 March 1999, we compared enoxaparin (1.5 mg/kg...
In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.Ten milliliters of plasma were collected at 4 time points: before NCT; 1 cycle; surgery; surgery. Customized droplet digital PCR (ddPCR) assays used track protein p53 (TP53) mutations previously characterized in tissue by massively parallel sequencing...
Abstract Background Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses. Methods The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) subsequent patient’s prognosis (overall OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients ESME nationwide multicentre database (Kaplan–Meier method). Results CNS occurred 4118 (24.6%)...
Abstract Introduction Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that reproduce the molecular characteristics their respective clinical tumors. In this work, we analyzed genomic and gene expression profiles human BC xenografts corresponding patient Methods Eighteen were obtained by grafting tumor fragments from patients into Swiss nude mice. Molecular characterization tumors was performed DNA copy number analysis using Affymetrix Microarrays....
BackgroundPalbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination endocrine therapy advanced luminal breast cancer (LBC). We evaluated the respective of chemotherapy letrozole–palbociclib (LETPAL) as neoadjuvant treatment patients high-risk LBC.Patients methodsNeoPAL (UCBG10/4, NCT02400567) randomised, parallel, non-comparative phase II study. Patients ER-positive, HER2-negative, Prosigna®-defined B, or A node-positive, stage II–III cancer, not candidate for...
HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, the molecular target predictive marker response to anti-HER2 agents. In a subset these cases, heterogeneous distribution gene amplification can be found, which creates clinically challenging scenarios. Currently, cancers with amplification/overexpression just over 10% cancer cells are considered HER2-positive for clinical purposes; however, it unclear as whether HER2-negative components such tumors would...
Abstract Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics outcome diagnosed with during breast cancer treatment Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up ICH on March 13, 2020, for all symptoms or radiologic signs. Registered data included patient history, tumor treatments, symptoms, radiological features, outcome. Data extraction done April...
Nonadherence to long-term treatments is often under-recognized by physicians and there no gold standard for its assessment. In breast cancer, nonadherence tamoxifen therapy after surgery constitutes a major obstacle optimal outcomes. We sought evaluate the rate of biochemical adjuvant using serum assessment examine effects on short-term, distant disease-free survival (DDFS).We studied 1,177 premenopausal women enrolled in large prospective study (CANTO/NCT01993498). Definition was based...
Tumor protein p53 (TP53) is mutated in approximately 30% of breast cancers, but this frequency fluctuates widely between subclasses. We investigated the mutation status 572 tumors, classified into luminal, basal and molecular apocrine subgroups. As expected, lowest was observed luminal (26%), highest (88%) tumors. Luminal tumors showed significantly higher substitutions (82 vs. 65%), notably A/T to G/C transitions (31 15%), whereas presented much frequencies complex mutations...
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse metastatic disease. Here we perform whole exome sequencing gene expression analysis matched primary tumours bone metastasis-derived patient-derived xenografts (PDX). Transcriptomic analyses reveal enrichment the G2/M checkpoint up-regulation Polo-like kinase 1 (PLK1) in PDX. PLK1 inhibition results tumour shrinkage highly proliferating...
Purpose: Paired primary breast cancers and metachronous metastases after adjuvant treatment are reported to differ in their clonal composition genetic alterations, but it is unclear whether these differences stem from the selective pressures of metastatic process, systemic therapies, or both. We sought define repertoire alterations cancer patients with de novo disease who had not received local therapy.Experimental Design: Up two anatomically distinct core biopsies synchronous distant nine...
Adverse effects of breast cancer treatment can negatively affect survivors' work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact related sequelae on employment.We used a French prospective cohort patients with stage I-III including 1,874 women who were working ≥ 5 years younger than legal retirement age (≤ 57 years) at diagnosis. Our outcome was nonreturn to (non-RTW) 2 after...
AimTo investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.MethodsMulticentre, open-label, non-comparative phase II study. Ninety-five randomised (2:1) receive four cycles CP ±3 concomitant 15 mg/kg...
The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior anastrozole absence of inhibition this patient population.To assess whether is when combined scenario.In international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015,...
We aimed to characterize long-term quality of life (QOL) trajectories among patients with breast cancer treated adjuvant chemotherapy and identify related patterns health behaviors.Female stage I-III receiving in CANTO (CANcer TOxicity; ClinicalTrials.gov identifier: NCT01993498) were included. Trajectories QOL (European Organisation for Research Treatment Cancer Quality Life Questionnaire-C30 Summary Score) associations trajectory group membership identified by iterative estimations...
Abstract Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic metabolomics analyses of patients’ tumours, metastasis-derived patient-derived xenografts (PDX) isogenic cell lines we demonstrate that fraction metastatic ER BC highly reliant on oxidative phosphorylation (OXPHOS). Treatment by the OXPHOS inhibitor IACS-010759 strongly inhibits tumour growth multiple...
Abstract Background Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. Methods We set up an ambispective bicentric cohort study to assess real-world effectiveness and safety of SG patients with mTNBC treated at Institut Curie Hospitals, a focus on brain metastases. Results This included 99 through French Early Access Program from May January 2023. Median age was 55 years...